What is sarcopenia, and how would you know if you were losing muscle?

Same weight. Same clothes. Less muscle. After midlife the tissue under your skin reorganises without the scale reporting any of it, and the part that fades fastest is not the muscle itself but what the muscle can do: strength falls around three times faster than mass. That gap is where the word sarcopenia lives. It is also why the two obvious things to measure turn out to be worth very different amounts.

What the word actually means now

Sarcopenia is the loss of muscle strength and muscle mass that accumulates with age.

It is not a synonym for being thin, and it is not confined to the very old. The current European consensus describes it as a muscle disease rooted in adverse muscle changes that accrue across a lifetime, common among older adults but able to begin earlier. It carries an ICD-10 diagnostic code, which in some countries means care for it can be billed.

What changed in the most recent revision is which measurement comes first. The consensus now treats low muscle strength as the defining feature, on the grounds the consensus itself gives: that strength is a more dependable measure of muscle function than quantity is. Low muscle quantity or quality is used to confirm the diagnosis rather than to make it, and poor physical performance is what marks a case as severe. That produces three tiers a clinic may use in those words:

Picture a tow rope. Its thickness is the easy thing to measure, and for a while thickness is a fair guide to what it can pull. Now imagine that some of the strands inside have been swapped for a soft filler that holds the rope's shape but takes no load, and that a few more have worked loose at the hook. Nothing about the outside has changed. The rope still measures the same across, and it pulls less than it did.

That is roughly the distinction between muscle quantity and muscle quality. Quantity is how much muscle tissue there is. Quality covers the microscopic and larger-scale aspects of muscle architecture and composition, including fat that has settled inside the muscle, and it is assessed by imaging rather than by a tape measure or a scale. Two people carrying the same amount of muscle can produce different amounts of force, and the reason usually sits in that second column.

Why strength and mass came apart

Because they decline at different speeds, and the difference is large enough to change which one is worth measuring.

A study that followed 1,880 older adults for three years measured both. Leg strength fell by 3.4 percent a year in white men, 4.1 percent in black men, 2.6 percent in white women and 3.0 percent in black women. Leg lean mass over the same period fell by about 1 percent a year. Strength was going about three times faster than the tissue producing it.

The part of that study worth sitting with is the part that found nothing. Among participants whose lean mass went up, strength did not follow. The coefficients were negative and nowhere near significance in either sex: in men, minus 0.48 plus or minus 4.61, p equals 0.92; in women, minus 1.68 plus or minus 3.57, p equals 0.64. Adding muscle over those three years told you very little about what happened to strength.

Two plausible results, and they lead different places.

• A scan says your lean mass is normal; your grip is weak. The current consensus would call that probable sarcopenia and ask for a confirming measurement. The scan has not cleared you, because strength is the parameter the definition leads with.
• A scan says your lean mass is low; your grip and walking speed are normal. Under the current consensus that is not sarcopenia, because low quantity confirms a diagnosis rather than making one. It may still be worth tracking, and it is a different conversation from the first.

Signal and noise, stated plainly: if you only look at two numbers from this appointment, look at the strength measurement and the walking speed. The mass figure is the supporting evidence, not the finding.

How a clinic actually looks for it

Mostly with four short tests, none of which involve a machine you lie inside.

You squeeze a hand dynamometer, a small spring-loaded handle, two or three times with each hand. You rise from a chair five times without using your arms while somebody times it. You walk four meters at your ordinary pace. Some clinics start with a five-question form, SARC-F, which asks about strength, walking, climbing stairs, rising from a chair, and falls. A body-composition scan may be added to measure appendicular lean mass, which is the muscle in your arms and legs.

Translating the outputs, using the European consensus thresholds:

The questionnaire has a specific limitation worth knowing before you fill one in: SARC-F has low to moderate sensitivity and very high specificity for low muscle strength. In ordinary terms, a positive answer set is informative and a negative one is much weaker evidence, because the form is built to find clear cases and will miss milder ones. It is a case-finding tool rather than a test.

The instruments themselves are covered elsewhere and not repeated here. Grip strength and walking speed goes through what a dynamometer reading is worth and why the number moves when the device does. DEXA scans explains the two different exams clinics sell off one machine, and which of them produces a lean mass figure at all.

Whose cut-off? Three expert groups, three answers

This is the part that changes what a result is worth, which is why it sits here rather than at the end.

Three bodies have published thresholds for the same measurement, and they do not agree. The European consensus sets low grip strength at under 27 kilograms in men and under 16 in women. A project run through the Foundation for the National Institutes of Health, pooling nine studies and more than 26,000 participants, set it at under 26 kilograms in men and under 16 in women, with low arm and leg muscle at under 19.75 kilograms in men and under 15.02 in women. A later consortium, pooling eight prospective cohorts covering 13,421 community-dwelling men and 4,828 women, put the same threshold at under 35.5 kilograms in men and under 20 in women, alongside a walking speed under 0.8 meters per second.

A grip of 30 kilograms in a man is therefore normal under two of those definitions and weak under the third. Nothing about the hand changed.

That third analysis also carries a null worth reading closely. It tested low grip strength, low scan-measured lean mass for height, and slow walking against four outcomes: falls, hip fractures, mobility limitation and death, with follow-up running from one year for falls to about nine years for mortality. Low grip strength was associated with those outcomes, usually independently of slowness, in both sexes, with odds and hazard ratios generally between 1.2 and 3.0. Lean mass measured by scan was not consistently associated with them. The consortium's conclusion was that grip strength and walking speed belong in a summary definition of sarcopenia; the scan figure did not earn a place on the strength of those results.

The same disagreement shows up in how common the condition looks. A systematic review covering 109 articles, 58 unique cohorts, 26 countries and 656 individual prevalence estimates found pooled prevalence in community-dwelling older adults of 9.9 percent under one definition, 12.9 percent under another, 18.6 percent under a third, and 24.2, 30.4 and 40.4 percent under three definitions based on muscle mass alone. Within a single definition the spread was wider still: estimates using the European criteria ranged from 0 to 36.7 percent in men and from 0 to 62.2 percent in women across cohorts, with between-study heterogeneity above 87 percent for every definition but one.

So a clinic telling you that you do or do not have sarcopenia is telling you which definition it uses as much as it is telling you about your body. That is a reasonable thing to ask about directly.

What is associated with slowing it, and what the trials found

Exercise has the better evidence of the two things usually sold alongside a result, and the evidence is narrower than the marketing around it.

A systematic review by an international sarcopenia initiative looked at 19 intervention studies, 7 of exercise and 12 of nutrition. Physical performance improved in most of the trials that measured it, and muscle strength improved as well. Muscle mass was the outcome that held up least often: it increased in 3 of the 7 exercise studies. The review's own summary of the field was that solid evidence on which to base recommendations for patients with sarcopenia is not available.

Protein supplements are the other half of that review, and the result is a clean negative. Its five moderate to high quality protein studies failed to show a consistent effect on muscle mass or function. A later meta-analysis of 36 randomized controlled trials covering 1,682 non-frail community-dwelling older adults tested five outcomes: lean body mass, handgrip strength, lower extremity muscle strength, gait speed and chair rise ability. None of the five reached significance against control. The authors' reading was that most participants were already eating enough protein, which is a different claim from protein not mattering, and it leaves the question open for people whose habitual intake is low.

The background rate is worth having as well. Muscle mass and strength peak somewhere around 30 to 35 years of age, then decline slowly and fairly steadily at first and faster after about 65 in women and 70 in men. Around 30 percent of adults over 70 report difficulty walking, rising from a chair or climbing stairs. That average decline can be substantially slowed by staying active, according to the National Institute on Aging, and slowed is the accurate word there rather than stopped.

One boundary, because it is easy to lose. Muscle strength is associated with better long-term outcomes. Measuring your grip is associated with nothing at all: the dynamometer is a ruler, and no ruler has ever moved the thing it measures. What a measurement can do is tell you where you are standing and give a later measurement something to be compared against.

Before you book

Worth asking, in an email, before you pay for anything:

• Which definition do you use, and what are your cut-offs? Three sets are in circulation and they disagree by a wide margin at the same grip. A clinic that can name its thresholds has thought about this.
• Which measurements are included? A strength test and a walking or chair-rise test are the ones the current consensus leads with. A body-composition scan on its own does not establish the diagnosis.
• If a result comes back low, what happens next? A measurement that changes nothing about the plan is a measurement you can decline.
• Will a retest use the same device and the same protocol? Grip readings move with the dynamometer model and with hand position, so a comparison across two different devices is not a clean comparison.
• Who reviews the result with me, and what are their qualifications?

Two limits to hold on to. A normal set of results here describes your muscle function on the day of the test; it does not rule out anything else, and it says nothing about the screening you are due for by age and risk. And this sits outside guideline-directed care rather than inside it, which is a reason to be clear about what you want from it rather than a reason to avoid it.